Cationic peptide carriers enable long-term delivery of insulin-like growth factor-1 to suppress osteoarthritis-induced matrix degradation

BACKGROUND: Insulin-like growth factor-1 (IGF-1) has the potential to be used for osteoarthritis (OA) treatment but has not been evaluated in clinics yet owing to toxicity concerns. It suffers from short intra-joint residence time and a lack of cartilage targeting following its intra-articular admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Vedadghavami, Armin, Hakim, Bill, He, Tengfei, Bajpayee, Ambika G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297664/
https://www.ncbi.nlm.nih.gov/pubmed/35858920
http://dx.doi.org/10.1186/s13075-022-02855-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297664/
https://www.ncbi.nlm.nih.gov/pubmed/35858920
http://dx.doi.org/10.1186/s13075-022-02855-1

Ejemplares similares